Education
About Us
Working with TipRanks
Follow Us
VistaGen Therapeutics (VTGN)
NASDAQ:VTGN
Total Valuation
VistaGen Therapeutics has a market cap or net worth of $58.32M. The enterprise value is $11.13M.
Market Cap$58.32M
Enterprise Value$11.13M
Share Statistics
VistaGen Therapeutics has 29,157,734 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding29,157,734
Owned by Insiders1.79%
Owned by Institutions41.12%
Financial Efficiency
VistaGen Therapeutics’s return on equity (ROE) is -0.26 and return on invested capital (ROIC) is -27.73%.
Return on Equity (ROE)-0.26
Return on Assets (ROA)-0.24
Return on Invested Capital (ROIC)-27.73%
Return on Capital Employed (ROCE)-0.28
Revenue Per Employee22.17K
Profits Per Employee-611.71K
Employee Count48
Asset Turnover<0.01
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of VistaGen Therapeutics is -3.56. VistaGen Therapeutics’s PEG ratio is -0.02.
PE Ratio-3.56
PS Ratio0.00
PB Ratio2.07
Price to Fair Value0.91
Price to FCF-0.50
Price to Operating Cash Flow-0.50
PEG Ratio-0.02
Income Statement
In the last 12 months, VistaGen Therapeutics had revenue of 1.06M and earned -29.36M in profits. Earnings per share was -1.52.
Revenue1.06M
Gross Profit1.06M
Operating Income-33.02M
Pretax Income-29.36M
Net Income-29.36M
EBITDA-32.45M
Earnings Per Share (EPS)-1.52
Cash Flow
In the last 12 months, operating cash flow was -39.23M and capital expenditures -28.70K, giving a free cash flow of -39.26M billion.
Operating Cash Flow-39.23M
Free Cash Flow-39.26M
Free Cash Flow per Share-1.35
Dividends & Yields
VistaGen Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta0.97
52-Week Price Change-38.08%
50-Day Moving Average2.30
200-Day Moving Average2.71
Relative Strength Index (RSI)33.77
Average Volume (3m)172.99K
Important Dates
VistaGen Therapeutics upcoming earnings date is Aug 7, 2025, TBA Not Confirmed.
Last Earnings DateJun 17, 2025
Next Earnings DateAug 7, 2025
Ex-Dividend Date―
Financial Position
VistaGen Therapeutics as a current ratio of 23.55, with Debt / Equity ratio of 22.51%
Current Ratio23.55
Quick Ratio23.55
Debt to Market Cap0.00
Net Debt to EBITDA3.61
Interest Coverage Ratio0.00
Taxes
In the past 12 months, VistaGen Therapeutics has paid 4.00K in taxes.
Income Tax4.00K
Effective Tax Rate>-0.01
Enterprise Valuation
VistaGen Therapeutics EV to EBITDA ratio is 0.39, with an EV/FCF ratio of 0.48.
EV to Sales-11.78
EV to EBITDA0.39
EV to Free Cash Flow0.48
EV to Operating Cash Flow0.49
Balance Sheet
VistaGen Therapeutics has $88.56M in cash and marketable securities with $1.71M in debt, giving a net cash position of -$86.85M billion.
Cash & Marketable Securities$88.56M
Total Debt$1.71M
Net Cash-$86.85M
Net Cash Per Share-$2.98
Tangible Book Value Per Share$5.90
Margins
Gross margin is 100.00%, with operating margin of -3103.48%, and net profit margin of -2759.59%.
Gross Margin100.00%
Operating Margin-3103.48%
Pretax Margin-2759.21%
Net Profit Margin-2759.59%
EBITDA Margin-3050.09%
EBIT Margin-3103.48%
Analyst Forecast
The average price target for VistaGen Therapeutics is $12.00, which is 11.43% higher than the current price. The consensus rating is Moderate Buy
Price Target$12.00
Price Target Upside500.00% Upside
Analyst ConsensusModerate Buy
Analyst Count2
Revenue Growth Forecast-33.00%
EPS Growth Forecast54.91%